Roche Reports meta-analysis Data for Ixekizumab in Autoimmune hepatitis

Roche today announced meta-analysis results for Ixekizumab in patients with Autoimmune hepatitis. The study demonstrated that Ixekizumab demonstrates favorable safety profile compared to standard of care or placebo. These results provide important insights into the treatment of Autoimmune hepatitis and support the continued development of Ixekizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Ixekizumab was consistent with previous observations, with no new safety signals identified.